Assignee
AVIDITY BIOSCIENCES INC
US·51 granted patents·31 pending applications·470 citations·filing 2017–2025
Top patents by PatentIndex Score
82 records- 0198US12064483B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2022·Granted Aug 20, 2024·19 cites·24 claims
- 0298US11446387B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Sep 20, 2022·8 cites·14 claims
- 0398US11400163B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Aug 2, 2022·26 cites·22 claims
- 0498US11311627B1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2021·Granted Apr 26, 2022·28 cites·24 claims
- 0598US11253607B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 22, 2022·7 cites·23 claims
- 0698US11246941B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 15, 2022·7 cites·23 claims
- 0798US11179472B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 23, 2021·35 cites·25 claims
- 0898US11028179B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 8, 2021·16 cites·20 claims
- 0998US10994020B2Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2018·Granted May 4, 2021·32 cites·24 claims
- 1098US10913800B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 9, 2021·19 cites·27 claims
- 1198US10881743B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2019·Granted Jan 5, 2021·55 cites·16 claims
- 1298US10787519B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 29, 2020·19 cites·17 claims
- 1398US10550188B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Feb 4, 2020·80 cites·13 claims
- 1497US11707532B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 25, 2023·3 cites·14 claims
- 1597US11576980B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 14, 2023·6 cites·23 claims
- 1697US11555190B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·15 cites·17 claims
- 1797US11525137B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Dec 13, 2022·13 cites·21 claims
- 1897US11497814B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Nov 15, 2022·3 cites·30 claims
- 1997US10487149B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Nov 26, 2019·21 cites·18 claims
- 2096US12049629B2Compositions and methods of treating Facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jul 30, 2024·2 cites·22 claims
- 2196US11999955B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jun 4, 2024·2 cites·16 claims
- 2296US11912779B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Feb 27, 2024·6 cites·17 claims
- 2396US11834510B2Anti-transferrin receptor antibodies and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Dec 5, 2023·4 cites·20 claims
- 2496US11583591B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Feb 21, 2023·2 cites·14 claims
- 2596US11554176B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jan 17, 2023·2 cites·16 claims
- 2696US11110180B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Sep 7, 2021·19 cites·20 claims
- 2795US12427202B2Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2023·Granted Sep 30, 2025·1 cites·9 claims
- 2895US12157774B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Dec 3, 2024·1 cites·5 claims
- 2995US12071485B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Aug 27, 2024·2 cites·13 claims
- 3095US10800848B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2018·Granted Oct 13, 2020·7 cites·16 claims
- 3195US2026007766A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3294US12104156B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Oct 1, 2024·1 cites·16 claims
- 3394US11872287B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Jan 16, 2024·1 cites·17 claims
- 3493US12006499B2Una amidites and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Jun 11, 2024·2 cites·8 claims
- 3593US11364302B1Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2021·Granted Jun 21, 2022·2 cites·20 claims
- 3693US2026060996A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 3791US12529056B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Granted Jan 20, 2026·0 cites·29 claims
- 3891US2024358736A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 3989US12359202B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2024·Granted Jul 15, 2025·1 cites·21 claims
- 4089US12071621B2Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skippingAVIDITY BIOSCIENCES INC·Filed 2023·Granted Aug 27, 2024·1 cites·21 claims
- 4189US2024287522A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4289US2025340880A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4388US12486328B2Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Granted Dec 2, 2025·0 cites·19 claims
- 4488US2024400707A1Compositions and methods of treating facioscapulohumeral muscular dystrophyAVIDITY BIOSCIENCES INC·Filed 2024·Application pending·0 cites
- 4587US2026014266A1Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4687US2025381285A1Compositions and methods of treating muscle dystrophyAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
- 4786US12263224B2Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Granted Apr 1, 2025·0 cites·15 claims
- 4885US2023047754A1Compositions and methods of treating muscle atrophy and myotonic dystrophyAVIDITY BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 4984US11578090B2Nucleic acid-polypeptide compositions and uses thereofAVIDITY BIOSCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·1 claims
- 5084US2025381286A1Nucleic acid-polypeptide compositions and methods of inducing exon skippingAVIDITY BIOSCIENCES INC·Filed 2025·Application pending·0 cites
Showing the top 50 of 82 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →